Phase II Study of Perbrolizumab Plus Lenvatinib in Combination with Belzutifan in patients with Solid Tumors (MK-4682-016), including Pancreatic Cancer
Summary
The purpose of this phase II trial is to evaluate the safety and efficacy of belzutifan in combination with pembrolizumab and Lenvatinib in patients with solid tumors, including pancreatic cancer.
General Information
NCT#: NCT04976634
Study ID: 6482-016
Trial Phase: Phase II
Trial Sponsor: Merck Sharp & Dohme Corp.
Therapies Used in This Trial: Pembrolizumab, Lenvatinib, Belzutifan